Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of Epstein-Barr virus-related (EBV) clinical diseases, from a benign mononucleosis-like illness to a fulminant non-Hodgkin's lymphoma. In the setting of hematopoietic stem cell transplantation, PTLD is an often-fatal complication occurring relatively early after transplant. Risk factors for the development of PTLD are well established, and include HLA-mismatching, T-cell depletion, and the use of antilymphocyte antibodies as conditioning or treatment of graft-versushost disease. Early recognition of PTLD is particularly important in the SCT setting, because PTLD in these patients tends to be rapidly progressive. Familiarity with the clinical features of PTLD and a heightened level of suspicion are critical for making the diagnosis. Surveillance techniques with EBV antibody titers and/or polymerase chain raction (PCR) may have a role in some highrisk settings. Immune-based therapies such as monoclonal anti-B-cell antibodies, interferon-a, and EBV-specific donor T cells, either as treatment for PTLD or as prophylaxis in high-risk patients, represent promising new directions in the treatment of this disease.
The increased risk of malignancy, and especially of lymphoid tumors, in solid-organ and hematopoietic stem cell transplant (HST) recipients has been recognized for over 30 years. [1] [2] [3] Post-transplant lymphoproliferative disorder (PTLD) represents a heterogeneous group of abnormal lymphoid proliferations, generally of B cells, that occur in the setting of ineffective T-cell function because of pharmacologic immunosuppression after organ transplantation. Unlike most other forms of non-Hodgkin's lymphoma, nearly all PTLDs are associated with Epstein-Barr virus (EBV) infection, as manifested by the presence of EBV within the malignant tissue. This review will provide an overview of PTLD and its association with EBV following solid-organ and HST.
Definition and classification
There is no universally accepted definition of PTLD. The term generally refers to a spectrum of B-cell hyperproliferative states, and includes benign conditions such as infectious mononucleosis-like illnesses, polyclonal lymphoid hyperplasia, and monoclonal malignancies such as B-cell (and occasionally T cell) lymphomas, which may take a fulminant course. 4 A number of attempts have been made to classify this disorder based on morphology, clonality, and disruption of nodal architecture (Table 1) .
Recommendations for a formal classification of PTLD were established by two international consensus groups and published in 1999. 5 According to these guidelines, the term 'PTLD' may encompass the full range of EBV-related lymphoproliferative states, including benign processes. However, when not otherwise specified, PTLD should refer to the neoplastic end of the PTLD spectrum. Neoplasia should be defined by two of the following three characteristics: (1) destruction of the underlying lymph node architecture; (2) monoclonality (regardless of morphology); (3) evidence of EBV infection in the neoplastic cells. They recommend subdividing PTLD into the categories described by Harris et al. 6 Typical monomorphic PTLD should be further characterized by the WHO 7 or REAL 8 lymphoma classification. Today, most groups accept this definition and classification of PTLD.
Pathophysiology
EBV was first implicated as a cause for malignancy in 1964, when viral particles were discovered in a patient with Burkitt's lymphoma. 9 Since then, EBV has also been implicated as a causative factor in nasopharyngeal carcinoma and Hodgkin's disease, as well as PTLD. A member of the herpes virus family, EBV infects and immortalizes B cells. EBV infection is usually asymptomatic in childhood. However, if the primary infection occurs during adolescence or adulthood, infectious mononucleosis occurs. Patients often demonstrate the classic triad of fever, lymphadenopathy, and pharyngitis. Activated T cells, apparent as atypical lymphocytes on the peripheral blood smear, are thought to be critical in modulating the proliferation of infected B cells during primary EBV infection. Ultimately, in immunocompetent people, the EBV genome forms an episome that remains latent in resting memory B cells. However, in certain immunocompromised patients, the critical T-cell control of B-cell The origin of the EBV in PTLD is varied. In solid-organ transplant patients, the PTLD cells are typically of recipient origin, suggesting that the EBV infection represents reactivation of prior quiesent virus. 11 Most cases of PTLD in allogeneic HST involve seropositive donors and recipients. The lymphoproliferation is believed to be donorderived because the host lymphoid system has been eradicated by the conditioning regimen, which often includes total body irradiation. Even in cases where the donor is seronegative, cases of PTLD have been shown to be of donor origin, suggesting that donor cells were infected with EBV after the transplant. Primary EBV infection may also result in PTLD, though this is more likely in children than in adults because of the prevalence of prior EBV infection in the adult population. [11] [12] [13] The theory that an inadequate T-cell response results in EBV-related B-cell proliferation is supported by the observed risk factors for the development of PTLD in transplantation. For solid-organ transplant patients, these include: an EBV-seronegative recipient (especially with an EBV-seropositive donor), development of a primary EBV infection (or occasionally, reactivation of EBV) after transplant, high levels of immunosuppression (cyclosporine, tacrolimus, antithymocyte globulin, or antilymphocyte antibodies), presence of cytomegalovirus disease, and possibly younger age (independent of EBV status). 4, 14 These factors manifest themselves as a higher risk of PTLD in patients with the most suppressed T-cell function. In solid-organ transplantation, pharmacologic immunosuppression is highest in lung transplant patients in whom the incidence of PTLD approaches 10%. 15, 16 Several factors have been identified in both solid-organ and stem cell transplants, which confer higher risk of developing PTLD (Table 2 ). In order to assess the role of T-cell immunity in the development of PTLD in allogeneic HST recipients, several groups have looked at immune reconstitution of EBV-specific cytotoxic T-cells post transplant. Reports have been conflicting in recipients of HLAmatched siblings. Crawford et al 17 first demonstrated an absence of CTLs against EBV-infected B cells in the first 3-6 months following HLA-matched allogeneic transplant, a finding confirmed by Lucas et al. 18 However, using different methods, Marshall et al 19 showed fairly rapid redevelopment of EBV-specific T-cell immunity in recipients of matched sibling HST, and demonstrated that the frequency of EBV-specific T cells correlates with the level of EBV genome expression in the peripheral blood. Recipients of Tcell-depleted (TCD) HST unequivocally lack EBV-specific T cells for several months after transplant. [18] [19] [20] In fact, adult recipients of TCD-unrelated HSTs have been shown to experience significant deficiencies of all CD3+, CD4+, and CD8+ T cells, compared to adult recipients of related HST and to pediatric recipients of all types of HST. 20 Rapid immune reconstitution has been observed after lowdose donor leukocyte infusions. 20 Risk factors for the development of PTLD after HST include T-cell depletion, HLA mismatch, specific antilymphocyte anti-graft-versushost disease (GVHD) therapies, and HST for primary immunodeficiency disorders. 11, 12, [21] [22] [23] Interestingly, in a recent report of 318 partially HLA-mismatched related donors, the incidence of PTLD was only 5.7%, despite the presence of several other known risk factors including Tcell depletion and use of antithymocyte globulin therapy. 24 The reasons for this disparity are unclear, but may be partly related to the relatively low autopsy rate. In several larger studies, the highest-risk group consists of patients who receive T-cell-depleted mismatched bone marrow 12 where patients are faced with near-complete deletion of both donor and host T cells and high levels of pharmacologic immunosuppression. The incidence in this group has been reported as high as 24%. 12 In most organ transplant patients who experience lower levels of immunosuppression, such as renal or liver transplant patients and recipients of standard T-cell-replete allogeneic HST, the risk of PTLD is on the order of 1-3%. 3, 11, 12 Rare EBV-related lymphoid tumors have been described in recipients of autologous stem cell transplants (HST). [25] [26] [27] These cases may be related to profound chemotherapyinduced general immunosuppression rather than T-cellspecific immunosuppression, and are a very rare complication of autologous HST.
While the majority of cases of PTLD are associated with EBV infection, there are cases with no evidence of EBV involvement. These EBV-negative PTLDs may comprise a distinct subgroup of PTLD: they tend to occur later after transplant (median of 50 months post transplant), to have a more malignant-appearing histology, and to behave more aggressively, with a reported median survival of 1 month. 28, 29 Like EBV-related PTLD, EBV-negative PTLD may still respond to reduction in immunosuppression and conventional chemotherapy.
Clinical features
PTLD may present in a myriad of ways, requiring diligent surveillance in appropriate patient populations to diagnose it. The median onset of disease in the solid-organ transplant population is 6 months and in HST recipients, 70-90 Table 2 Risk factors for developing PTLD
Solid-organ transplantation Allogeneic stem cell transplantation
Lung or heart-lung transplant T-cell depletion EBV-seronegative recipient with EBV-seropositive donor HLA-mismatching (related or unrelated; synergistic with T-cell depletion) Specific antilymphocyte therapy Specific antilymphocyte therapy High levels of immunosuppression Primary immunodeficiency as indication for transplant days. 4, 16 However, cases have been reported as early as 1 week and as late as 9 years post transplant. 16 Symptoms are diverse and may be related to viral infection, mass effect, organ dysfunction, or lymphoma-related B symptoms. Clinical features of PTLD in allogeneic HST recipients are similar to those of solid-organ transplant recipients, but there appears to be a greater incidence of fulminant, disseminated disease, perhaps accounting for the increased mortality seen in this population. Infection, usually aspergillus and cytomegalovirus, complicates many cases. In general, any transplant patient who experiences adenopathy, mass lesions, fever, unexplained pain, weight loss, or dysfunction of the transplanted organ should be evaluated for PTLD. Of note, PTLD may be very difficult to distinguish from episodes of organ rejection and infection. Active awareness of PTLD is important for the early diagnosis, while other etiologies of symptoms are under evaluation. Given the myriad other diagnoses that PTLD may mimic, tissue biopsy confirmation of PTLD is required. Special studies to confirm the diagnosis of PTLD include immunophenotyping by flow cytometry or immunohistochemistry, and molecular studies such as fluorescent in situ hybridization for EBV early RNA (EBER) and polymerase chain reaction (PCR) for the EBV genome. PTLD should be strongly considered when empiric increases in immunosuppression result in worsening organ dysfunction. 4 Overall mortality of PTLD is difficult to establish, given the heterogeneity of presentation, underlying conditions, and therapies; however, estimates of approximately 40-70% have been reported after solid-organ transplantation. 30 After HST, early mortality rates for PTLD approached 90%. In one study, the risk factors that adversely affected survival were stem-cell rather than solid-organ transplant, HST for a hematologic malignancy rather than an immunodeficiency disorder, and four or more sites of disease. 31 More recently, survival has improved significantly with the advent of donor lymphocyte infusion (DLI) therapy.
Staging of PTLD has not been formally defined. We recommend following conventional staging for non-Hodgkin's lymphoma by obtaining computed tomography of the chest, abdomen, and pelvis as well as a serum LDH for prognostic purposes. 16 EBV PCR of peripheral blood may be useful at the time of diagnosis and during follow-up as methods of monitoring patient's response to treatment. At this time, it is unclear whether results of bone marrow biopsy alter outcome or management in patients with normal blood counts.
Surveillance
Early detection of PTLD may allow for prompt therapy and potentially decrease mortality. Experience with monitoring for PTLD is limited, and there are no prospective randomized clinical trials of early interventions. However, several compelling reports suggest that surveillance for the presence of primary or reactivated EBV infection may prove useful, and there are small series suggesting that some therapies may thwart the development of PTLD.
Several groups have examined both solid-organ transplant and HST recipients for evidence of active EBV infection. EBV activity can be assessed in a number of ways, including evaluation of EBV viral load in the peripheral blood (as measured by PCR amplification), measurement of the number of EBV-infected peripheral blood mononuclear cells, and ex vivo spontaneous growth of EBV-transformed B cells. [32] [33] [34] [35] [36] [37] Serology for antibodies to EBV viral capsid antigen or nuclear antigen is less sensitive than these methods, but is more specific for EBV disease; however, these tests are not routinely available in all clinical chemistry labs and thus results may be delayed. By all of these measures, it has been demonstrated that EBV activity is greater in transplant recipients with PTLD than in transplant recipients without PTLD, healthy EBV-seropositive adults, or healthy adults with infectious mononucleosis. Furthermore, these EBV-related markers tend to rise in the weeks prior to development of clinical PTLD and to peak at the time of diagnosis of PTLD, 33, 35, 36, 38 implying that their measurement may be used as predictors of the development of PTLD. Although the studies were small, negative predictive values (94-100%) and sensitivities (100%) were quite high. 36, 37, 39 It is interesting to note that EBV DNA levels decrease with anti-EBV therapy, 35, 37 although this may not always correlate with the PTLD tumor response. 40 Thus, while measurement of EBV viral load is biologically appealing as a predictive test, the clinical utility remains to be determined.
Prophylaxis and treatment

Antiviral therapy
Initial attempts to prevent PTLD in the solid-organ transplant population were focused primarily on using antiviral therapies, such as thymidine kinase inhibitors ganciclovir or acyclovir, to eradicate or control EBV for high-risk patients (Table 3a) . These drugs inhibit the replication of other herpes viruses, such as herpes simplex and cytomegalovirus. In vivo, however, they are ineffective against EBV, because EBV survives as an episome outside of the lymphocyte's genome. In addition, these drugs do not eradicate latently infected B cells. 41, 42 The reports that prophylactic antiviral drugs minimize PTLD risk have been somewhat unconvincing, involving very small number of patients in observational studies. Each investigator defined 'high-risk' differently: some included only patients with elevated EBV viral loads, while others included EBVnegative patients receiving organs from EBV-positive donors, or patients receiving high-dose immunosuppression or specific antilymphocyte therapy. This inconsistency further complicates the interpretation of these studies. Anecdotal reports of acyclovir or ganciclovir for successful treatment of PTLD have not been substantiated. 30 However, virtually all other therapies have been combined with high-dose antiviral therapy, usually acyclovir. Thus, it is difficult to assess the true utility of antivirals as adjuncts to other treatments. An interesting approach involving arginine butyrate to induce latent EBV thymidine kinase expression, followed by treatment with ganciclovir, 
Pediatric lung
Allogeneic peripheral blood mononuclear cells (1 Â 10 6 CD3+ cells/kg) from an EBV-seropositive, HLA-identical sibling given three times over 9 months+XRT to treat PTLD in CNS (multiple brain lesions)
Case report: CR 9 months after last infusion of PBMCs, with severe bronchiolitis obliterans and chronic graft rejection Lymphoproliferative disorder AW Loren et al produced a response in five of 10 patients in an early trial.
Reduction of immunosuppression
The mainstay of therapy for PTLD is reduction of immunosuppression. The effectiveness of this intervention was described initially by Starzl et al 44 in 1984 (Table 3b ) and has been substantiated recently. 16 Predictors of lack of response to reduction of immunosuppression include a serum LDH42.5 times the upper limit of normal, organ dysfunction, and multiple visceral sites of disease. Patients who lacked all of these risk factors had an 89% response rate, whereas the presence of two or more risk factors predicted a very poor prognosis, with no patients responding. 16 While reduction in immunosuppression is the most established therapy for PTLD, there are significant risks with this treatment. In solid-organ transplant patients, graft rejection occurs as a potential complication in 39% of both responders and nonresponders. 16 In renal allograft recipients, in whom hemodialysis is an effective 'backup' therapy, this occurrence is not life-threatening. Aggressive reduction in immunosuppression may be attempted in these patients, including complete cessation of immunosuppression if required. In patients with life-sustaining organ transplants such as hearts, livers and lungs, reduction in immunosuppression should be more moderate and closely monitored as allograft rejection may be swift and fatal. In allogeneic HST, complications from decreased immunosuppression typically manifest themselves as increased risk for GVHD with significant risk for morbidity and mortality. Proper institution of reduction in immunosuppression represents a challenge to the physician that requires careful patient individualization. 16, 30 EBV status does not predict response to reduction of immunosuppression; 16 in fact, EBV-negative PTLDs have been shown to respond to reduction in immunosuppression. 28, 29 Hence, this maneuver should be attempted in patients with EBV-negative tumors as well in those with classic EBV-related PTLD.
Local treatment
When possible, complete surgical excision of localized disease is highly effective. Localized disease treated with definitive local therapy (surgery or radiation), combined with reduction of immunosuppression, has an excellent prognosis, with PTLD-related mortality rates reported between 0 and 26% (Table 3c) . 16, 30, 45 Cytokine therapy Attempts to establish a competent immune system to control EBV-related lymphoproliferations, with immune modulators such as cytokines with or without immunoglobulins have been made. Several case series and case reports have described responses to interferon-alpha and interferon-alpha combined with intravenous IgG (Table 3d) . 12, 21, 45, 46 Interleukin-6, a cytokine that promotes the growth and proliferation of B cells, provides another potential target. It is difficult to assess the effectiveness of cytokine therapy as most studies utilizing these agents have also incorporated concurrent reduction in immunosuppression or antiviral agents. Early reports are encouraging 12, 30, [45] [46] [47] and merit further study.
Cytotoxic chemotherapy
Chemotherapy has also been used to treat PTLD, generally after patients have failed to respond to surgical excision with or without reduction of immunosuppression. Regimens are similar to those used for non-Hodgkin's lymphoma, such as CHOP and ProMACE-CytaBOM. While chemotherapy may occasionally provide long-term relapse-free survival, it is accompanied by a high infection and mortality rate (Table 3e) .
48,49
Anti-B cell antibodies
A promising therapeutic option to control B-cell proliferation is anti-B-cell antibody therapy. Expression of B-cell antigens is variable in PTLD, most likely because of the dysregulation by EBV infection. Nevertheless, results have been quite promising with many patients achieving longterm relapse-free survival (Table 3f) . Predictors for poor response to anti-B-cell therapy include multivisceral disease, late-onset PTLD (41 year post-transplant), and CNS involvement. 31 Successes with the initial use of murine monoclonal antibodies led to the use of rituximab (humanmouse chimeric monoclonal anti-CD20 antibody). A subsequent report of five patients with PTLD treated with rituximab demonstrated a decrease in EBV viral load in all patients, but progression of the PTLD tumor in three patients, 40 questioning the accuracy of following EBV DNA levels in patients receiving rituximab. In addition to 'naked' monoclonal antibodies, anti-B-cell antibodies linked to radionuclides such as tositumomab (anti-CD20 linked to iodine-131) and ibritumomab tiuxetan (anti-CD20 linked to yttrium-90) appear hopeful and warrant additional studies.
Cellular immunotherapy
In allogeneic HST patients, there is another option for both prevention and treatment: cellular or adoptive immunotherapy. As noted above, the lymphocyte populations in recipients of allogeneic HST are abnormal, particularly after T-cell depleted or HLA-mismatched transplants. It is clear that the latter group of patients has markedly decreased T-and B-cell numbers and function for at least 6 months and possibly several years after transplant. 17, 19, 20, 50 PTLD risk increases in the setting of T-cell regulatory dysfunction. As the frequency of EBV-specific CD8+ T cells rises after HST, both a decrease in EBV viral load 51 and regression of PTLD 18, 50, 52 have been observed. In addition, the efficacy of unselected donor leukocytes in reconstituting the recipient's immune system has been well described. 20 These two observations have led to attempts both to prevent and to treat PTLD with donor leukocyte infusions. Initial treatment with unselected donor mononuclear cells resulted in high response rates, but carried a significant risk of GVHD. 53, 54 However, over 90% of patients may respond to DLI. In donors previously exposed to EBV, the frequency of viral-specific cytotoxic T cells (CTLs) will be higher than in the initially infected host, and it is possible that low-dose DLI may be given to eradicate PTLD, and hence minimize the risk of GHVD. Rather than using unselected DLI, more targeted cellular immunotherapy utilizing CTLs directed against EBV holds the promise of more active antiviral/tumor effect without the risk of GVHD (Table 3g) . 55 Rooney et al 34, 56 showed that EBV-specific CTLs could be used prophylactically and as primary therapy for PTLD after allogeneic bone marrow transplantation. A compelling argument has been made that CTLs may be most effective as prophylaxis in patients with high EBV viral loads; at this point in the disease course, there is minimal tumor burden and thus a lower chance of selecting escape mutants. 57 However, the significant resources and logistics associated with the creation of patient-specific EBV-specific CTLs limits the widespread use of this treatment. The option of using EBVspecific CTLs may not be limited to allogeneic HST recipients. An 11-year-old boy with CNS PTLD after a cadaveric HLA-mismatched lung transplant was treated with his HLA-identical brother's peripheral blood mononuclear cells, and achieved complete remission, although his course was complicated by several bouts of acute rejection of the transplanted lungs. 58 In a recent report, a patient died of progressive PTLD despite treatment with EBV-specific CTLs. Post-mortem examination of this patient's tumor revealed a deletion in the tumor virus antigen EBNA-3B, which altered the tumor's HLA-restricted epitopes and rendered it unresponsive to the donor CTL infusion, which was directed against the wild-type EBNA-3B epitope. 59 The mutated virus appeared to have originated in the recipient after transplant. This case report demonstrated the possibility of EBV 'escape mutants' and a potential limitation of this therapy.
The reports of successful CTL therapy in the allogeneic HST population prompted Nalesnik et al 60 to give autologous lymphokine-activated killer (LAK) cells to solid-organ transplant recipients with PTLD. In this seven-patient series, peripheral blood mononuclear cells were collected from patients with PTLD and cultured with recombinant human IL-2, and reinfused. All the four patients with EBV-positive tumors sustained involution of their tumors; two patients suffered organ rejection as a complication of this therapy. 60 More recently, three patients donated T cells prior to solid-organ transplantation. EBV-specific cell lines were cultured and reinfused into the patients after transplant as PTLD prophylaxis. Their circulating EBV DNA levels were suppressed to below pretransplant levels, and EBV-specific CTLs were measurable in the patients' blood for 3 months after transplant. 61 Thus, use of either autologous or HLAmatched allogeneic CTLs may have a promising future in effective treatment or prevention of PTLD in the solidorgan transplant population, as well.
Conclusion
PTLD is an often-fatal complication of both solid-organ and stem cell transplantation. Early diagnosis of PTLD is important and requires high levels of clinical vigilance. Surveillance for PTLD by monthly PCR for circulating EBV DNA may be appropriate, particularly in such highrisk settings as EBV-seromismatched (donor-positive, recipient-negative) solid-organ transplants and T-cell-depleted, HLA-mismatched stem cell transplants. When possible, surgical excision of the node, mass, or affected organ should be pursued to establish a diagnosis. Reduction in immunosuppression remains the primary therapy for PTLD and can often result in permanent disease eradication. Further therapies should be tailored to the patient and the clinical situation. Current options include anti-B-cell antibodies, antiviral drugs, or conventional chemotherapy. However, taking advantage of the unique immune status of these patients may ultimately prove to be an even more successful intervention. Adoptive immunotherapy with EBV-specific donor T cells is highly effective and appears to be less associated with GVHD disease than unselected allogeneic donor leukocyte infusion. Use of cellular therapy as a prophylaxis against PTLD with pre-emptive infusion of EBV-specific CTLs either in all high-risk HST recipients or in patients with increasing EBV viral loads may be practical for widespread use in the future.
Although rare, PTLD warrants intensive future studies, given the increasing numbers of all types of transplants and the high mortality of this disease. PTLD is a biologically fascinating disorder that greatly illuminates the roles of the immune system and viral infection in the development of malignancy. Therapy of PTLD provides a prime and exciting example of successful immunotherapy of cancer that may have implications for other malignancies and viral infections.
